These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23752091)

  • 21. Targeting glutamate homeostasis for potential treatment of nicotine dependence.
    Alasmari F; Al-Rejaie SS; AlSharari SD; Sari Y
    Brain Res Bull; 2016 Mar; 121():1-8. PubMed ID: 26589642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.
    Buchhalter AR; Fant RV; Henningfield JE
    Drugs; 2008; 68(8):1067-88. PubMed ID: 18484799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation.
    Markou A; Paterson NE; Semenova S
    Ann N Y Acad Sci; 2004 Oct; 1025():491-503. PubMed ID: 15542754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism-based medication development for the treatment of nicotine dependence.
    Xi ZX; Spiller K; Gardner EL
    Acta Pharmacol Sin; 2009 Jun; 30(6):723-39. PubMed ID: 19434058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prefrontal gamma-aminobutyric acid type A receptor insertion controls cue-induced relapse to nicotine seeking.
    Lubbers BR; van Mourik Y; Schetters D; Smit AB; De Vries TJ; Spijker S
    Biol Psychiatry; 2014 Nov; 76(9):750-8. PubMed ID: 24631130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropeptide systems and new treatments for nicotine addiction.
    Bruijnzeel AW
    Psychopharmacology (Berl); 2017 May; 234(9-10):1419-1437. PubMed ID: 28028605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A glimpse into the future - Personalized medicine for smoking cessation.
    Bierut LJ; Johnson EO; Saccone NL
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):592-9. PubMed ID: 24055496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotinic activation of laterodorsal tegmental neurons: implications for addiction to nicotine.
    Ishibashi M; Leonard CS; Kohlmeier KA
    Neuropsychopharmacology; 2009 Nov; 34(12):2529-47. PubMed ID: 19625996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging pharmacotherapies for smoking cessation.
    Garwood CL; Potts LA
    Am J Health Syst Pharm; 2007 Aug; 64(16):1693-8. PubMed ID: 17687057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal.
    Barik J; Wonnacott S
    Mol Pharmacol; 2006 Feb; 69(2):618-28. PubMed ID: 16269536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.
    Simmons SJ; Gould TJ
    J Clin Pharm Ther; 2014 Oct; 39(5):457-67. PubMed ID: 24828779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanisms underlying behaviors related to nicotine addiction.
    Picciotto MR; Kenny PJ
    Cold Spring Harb Perspect Med; 2013 Jan; 3(1):a012112. PubMed ID: 23143843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype.
    Brunzell DH
    Nicotine Tob Res; 2012 Nov; 14(11):1258-69. PubMed ID: 22492084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.
    Mineur YS; Brunzell DH; Grady SR; Lindstrom JM; McIntosh JM; Marks MJ; King SL; Picciotto MR
    Genes Brain Behav; 2009 Apr; 8(3):257-66. PubMed ID: 19077117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic nicotine and withdrawal affect glutamatergic but not nicotinic receptor expression in the mesocorticolimbic pathway in a region-specific manner.
    Pistillo F; Fasoli F; Moretti M; McClure-Begley T; Zoli M; Marks MJ; Gotti C
    Pharmacol Res; 2016 Jan; 103():167-76. PubMed ID: 26631628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.
    Yuan M; Malagon AM; Yasuda D; Belluzzi JD; Leslie FM; Zaveri NT
    Behav Brain Res; 2017 Aug; 333():251-257. PubMed ID: 28693859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobacco/nicotine and endogenous brain opioids.
    Xue Y; Domino EF
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1131-8. PubMed ID: 18215788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Nicotinic Modulation of Glutamatergic and GABAergic VTA Microcircuits.
    Yan Y; Beckley NA; Kim VJ; Drenan RM
    eNeuro; 2019; 6(6):. PubMed ID: 31744841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecules and circuits involved in nicotine addiction: The many faces of smoking.
    Picciotto MR; Mineur YS
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):545-53. PubMed ID: 23632083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetic components of alcohol and nicotine co-addiction: from genes to behavior.
    Schlaepfer IR; Hoft NR; Ehringer MA
    Curr Drug Abuse Rev; 2008 Jun; 1(2):124-34. PubMed ID: 19492010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.